Bimekizumab 3-Year Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis: Response Maintenance, Re-treatment, and Effect on High-Impact Areas
Eleanor Roberts
Abstract:Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, both members of the IL-17 family of proinflammatory cytokines. Bimekizumab provides rapid and long-term response in patients with moderate-to-severe plaque psoriasis. At the European Academy of Dermatology and Venereology (EADV) 2023 Congress, three posters were presented reporting 3-year results from the Phase III/IIIb clinical trials of bimekizumab in plaque psoriasis.
The first poster focused on the subgroup o… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.